Experimental and clinical psychopharmacology最新文献

{"title":"Identification and management of nonsystematic cross-commodity data: Toward best practice.","authors":"Mark J Rzeszutek, Sean D Regnier, Brent A Kaplan, Haily K Traxler, Jeffrey S Stein, Devin C Tomlinson, Mikhail N Koffarnus","doi":"10.1037/pha0000836","DOIUrl":"10.1037/pha0000836","url":null,"abstract":"<p><p>Data systematicity has been an important area of consideration for behavioral economic demand. Stein et al. (2015) introduced criteria and an accompanying algorithm to aid researchers in identifying data series that may be considered \"nonsystematic\"-that is, data that may not follow empirically based assumptions such as an overall decrease in consumption as the cost of a commodity increases and consistency in decreases in consumption. However, those criteria and algorithm are only directly applicable to own-price demand, or demand for a commodity that is increasing in price. Cross-price demand, or demand for a second commodity that changes as a function of some other commodity, does not have a similar set of criteria or algorithm for assessing cross-commodity demand systematicity. Cross-price or cross-commodity demand is useful in understanding how changes in one substance or commodity may change the consumption of another substance or commodity. Thus, we extend Stein et al.'s criteria and algorithm to classify if a cross-commodity can be considered a substitute, complement, or independent, and then assess its systematicity based on its classification. We demonstrate this algorithm on three different cross-commodity demand data sets and describe important considerations regarding data exclusions to prevent biasing results from own-price and cross-price demand. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"363-373"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12970609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing cannabis use is associated with increased social discount rates and decreased self-reported social use in college students.","authors":"Paul Romanowich, Celia Connor-Smith, Kendyl Eugenio, Presley Nelson","doi":"10.1037/pha0000849","DOIUrl":"10.1037/pha0000849","url":null,"abstract":"<p><p>Cannabis use has increased in parallel with college-aged individuals as recreational cannabis legalization increases. Temporal discounting studies with licit and illicit substances have shown that substance use frequency is positively associated with steeper discount rates. However, temporal discounting studies targeting cannabis use have shown either a small or no positive association between substance use frequency and discount rates. A previous social discounting study reported that current cannabis use participants showed significantly steeper discount rates relative to participants who self-reported no cannabis use. The present study extends those findings by focusing on current cannabis use participants to determine whether cannabis use frequency is correlated with decreased cannabis sharing. In addition, given the purported social nature of cannabis use, the present study examined associations between cannabis use frequency and self-report social use patterns. Eighty-nine college students self-reported current cannabis use rates via a cannabis engagement questionnaire and completed a social discounting task for cannabis. Results showed that cannabis use participants above the median (>4 cannabis use days in the past 30 days) shared significantly less hypothetical cannabis, relative to participants below the median (≤4 use days in the past 30 days). In addition, participants above the median were significantly less likely to self-report using cannabis \"always or almost always with other people.\" These results extend previous findings that social discount rates are significantly associated with increased cannabis use within a social context. Implications for quantitative models assessing cannabis value and potential clinical diagnosis are discussed. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"417-425"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147498016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Rapid cognitive screening of patients with substance use disorders\" by Copersino et al. (2009).","authors":"","doi":"10.1037/pha0000868","DOIUrl":"10.1037/pha0000868","url":null,"abstract":"<p><p>Reports an error in \"Rapid cognitive screening of patients with substance use disorders\" by Marc L. Copersino, William Fals-Stewart, Garrett Fitzmaurice, David J. Schretlen, Jody Sokoloff and Roger D. Weiss (<i>Experimental and Clinical Psychopharmacology</i>, 2009[Oct], Vol 17[5], 337-344; see record 2009-17802-007). In the article, scoring instructions in the MoCA Assessment subsection of the Method section included an erroneous parenthetical statement: \"(31 if the patient is age 12 or younger).\" This statement should have read \"(with one point added if the patient has 12 years or fewer of formal education).\" This error does not reflect how assessment data were collected in the study and does not affect the results or the conclusions drawn from the data. (The following abstract of the original article appeared in record 2009-17802-007). To date, there has not been a time-efficient and resource-conscious way to identify cognitive impairment in patients with substance use disorders (SUDs). In this study, we assessed the validity, accuracy, and clinical utility of a brief (10-min) screening instrument, the Montreal Cognitive Assessment (MoCA), in identifying cognitive impairment among patients with SUDs. The Neuropsychological Assessment Battery-Screening Module, a 45-min battery with known sensitivity to the mild to moderate deficits observed in patients with SUDs, was used as the reference criterion for determining agreement, rates of correct and incorrect decision classifications, and criterion-related validity for the MoCA. Classification accuracy of the MoCA, based on receiver operating characteristic (ROC) analysis, was strong, with an area under the ROC curve of 0.86, 95% confidence interval [0.75, 0.97]. The MoCA also showed acceptable sensitivity (83.3%) and specificity (72.9%) for the identification of cognitive impairment. Using a cutoff of 25 on the MoCA, the overall agreement was 75.0%; chance-corrected agreement (kappa) was 41.9%. These findings indicate that the MoCA provides a time-efficient and resource-conscious way to identify patients with SUDs and neuropsychological impairment, thus addressing a critical need in the addiction treatment research community. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"386"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of oral cannabidiol (CBD) on spontaneous opioid withdrawal in male and female rats.","authors":"Bryan W Jenkins, Cerina Pang, Robbie Y Kuang, Elise M Weerts, Catherine F Moore","doi":"10.1037/pha0000826","DOIUrl":"10.1037/pha0000826","url":null,"abstract":"<p><p>Opioid use disorder remains a public health crisis in the United States. A key factor in continued use, relapse risk, and overdose is the severe withdrawal syndrome that accompanies abstinence. Observational studies suggest cannabis may improve outcomes for patients with opioid use disorder and cannabidiol (CBD), a nonintoxicating compound found in cannabis, is being investigated as a potential treatment. This study investigated whether CBD alleviated withdrawal symptoms in a rat model of opioid dependence. Sprague-Dawley rats (<i>N</i> = 100, 50% female) were administered escalating doses of morphine across 10 days (10-50 mg/kg, twice daily). Following abrupt discontinuation, withdrawal outcomes were evaluated across acute (38-hr) and protracted (up to Day 7) timepoints. Rats were treated daily with oral CBD (10 or 30 mg/kg, p.o.) or sesame oil vehicle, beginning 14-hr after their final morphine or saline injection. Withdrawal severity was assessed through physical measurements of body weight, food intake, and somatic signs (e.g., body shakes, diarrhea), pain sensitivity, and measurements of anxiety-like behaviors in the protracted phase. Compared to nondependent controls, morphine-dependent rats had decreased body weight and food intake, showed greater somatic signs, and had increased pain sensitivity that peaked in acute withdrawal (38-hr). In the protracted phase, limited withdrawal signs and no anxiety-like behaviors were detected. Oral CBD did not affect symptoms of opioid withdrawal. These data indicate that CBD alone may have limited effectiveness for treating opioid withdrawal. Reports of improved withdrawal symptoms after cannabis use may be attributed to other compounds in cannabis. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"408-416"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the abuse liability of U.S. Food and Drug Administration-authorized electronic nicotine delivery systems: Impact of nicotine flux, flavor, and menthol cigarette smoking status.","authors":"Elizabeth O Ogunleye, Rose S Bono, Rabia Imran, Nicoleta Gaitan, Thokozeni Lipato, Andrew J Barnes, Caroline O Cobb","doi":"10.1037/pha0000861","DOIUrl":"10.1037/pha0000861","url":null,"abstract":"<p><p>The U.S. Food and Drug Administration has authorized 41 electronic nicotine delivery systems (ENDS) that meet its public health standard. This clinical lab study utilized behavioral economic and subjective measures to index the abuse liability of currently authorized ENDS that varied in nicotine flux (i.e., μg nicotine/s) and flavor among adults who smoke cigarettes. Using a Latin square-ordered, within-subject design, adults who smoke cigarettes (<i>n</i> = 30; 20 menthol preferring [MP]) completed four sessions: one with own-brand cigarettes and three with tobacco and menthol flavors of three NJOY-branded ENDS: 2.4% nicotine (58 μg/s flux), 5% nicotine (118-123 μg/s flux), 6% nicotine (61-65 μg/s flux). Outcomes included behavioral economic indices (e.g., price sensitivity) and subjective measures (e.g., product acceptability). Mixed analysis of variance was used to examine the effects of ENDS nicotine flux, flavor, and MP. MP participants were less price sensitive than those who smoked nonmenthol, particularly for menthol-flavored ENDS. Those who smoked nonmenthol were less price sensitive for tobacco-flavored versus menthol-flavored ENDS. MP participants substituted all ENDS for own-brand cigarettes, while those who smoked nonmenthol only substituted with lower flux tobacco-flavored and higher flux menthol-flavored ENDS. Greater positive ratings on some acceptability measures were observed for menthol-flavored than tobacco-flavored ENDS. Those who smoked nonmenthol reported greater aversive ENDS-related sensory effects than MP participants. Menthol flavoring in ENDS increased some abuse liability measures, particularly product acceptability. ENDS abuse liability and substitution potential also varied by MP. Lower flux tobacco and higher flux menthol ENDS may support switching. Findings support further investigation on menthol-flavored, higher flux ENDS for public health benefit. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"374-386"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13367412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148435516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring risk tolerance among individuals who use opioids.","authors":"Sahana Lothumalla, Devin C Tomlinson, Maya Campbell, Mary Jannausch, Chelsea Wilkins, Nathan Menke, Maureen A Walton, Erin E Bonar, Jason Goldstick, Lewei A Lin, Lara N Coughlin","doi":"10.1037/pha0000844","DOIUrl":"10.1037/pha0000844","url":null,"abstract":"<p><p>Higher overdose risk may be influenced by risk tolerance, which may influence risky behaviors for individuals who misuse opioids and/or stimulants. We investigate overdose-related risk tolerance in this population. Adults (18-75 years, <i>N</i> = 181) with past-month opioid misuse and phone access remotely completed a questionnaire on demographics, substance use, preferred opioid, and an overdose probabilistic discounting task (i.e., risk tolerance). Regression models compared opioid preferences (street vs. prescription) and/or costimulant use (vs. no use) on the outcome of risk tolerance. In the sample, 53% and 47% preferred to use/misuse street and prescription opioids, respectively. Overdose risk tolerance was significantly higher for individuals who use street opioids compared to individuals who use prescription opioids (p < .001). Risk tolerance was significantly higher among those who used fentanyl (area under the curve [AUC] <i>M</i> ± <i>SD</i> = 0.56 ± 0.23) compared to heroin (AUC <i>M</i> ± <i>SD</i> = 0.44 ± 0.24; <i>p</i> = .031), prescription opioids (AUC <i>M ± SD</i> = 0.24 ± 0.21; <i>p</i> = .032), and medication for opioid use disorder (AUC <i>M ± SD</i> = 0.38 ± 0.27; <i>p</i> = .004). Street opioids (<i>F</i> = 35.09, <i>p</i> < .0001) and stimulant use severity (<i>F</i> = 4.51, <i>p</i> = .035) were significantly associated with increased risk tolerance. Individuals who prefer fentanyl and those with high stimulant use severity show the highest overdose risk tolerance and should continue to be prioritized for interventions to reduce overdose risk. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"453-459"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147812932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The quantitative economon model as a novel computational tool for addiction research.","authors":"Jeremy M Haynes, Joel Correa da Rosa, Eduardo R Butelman, Steven R Hursh, S Stevens Negus","doi":"10.1037/pha0000835","DOIUrl":"10.1037/pha0000835","url":null,"abstract":"<p><p>An economon is a dyadic economic unit of two participants who exchange mutually reinforcing commodities (e.g., addictive substances for money). A human economon often consists of a buyer providing money to a supplier, while the supplier reciprocally provides some commodity to the buyer. Here, we develop the quantitative economon model to characterize transactional behavior between individual buyers and suppliers. According to the model, transactions between a buyer and supplier depend on their respective economic demand for the commodities exchanged. Additionally, the model assumes that demand for a given commodity will fluctuate across sequential transaction opportunities. When transactions succeed, commodities are exchanged and consumed, and demand declines on the subsequent encounter due to satiation. When transactions fail, commodities are <i>not</i> exchanged, and demand increases on the subsequent encounter due to deprivation. Using a computational implementation of the quantitative economon model, we simulated transaction patterns maintained by four hypothetical situations with high or low levels of deprivation crossed with high or low levels of satiation (i.e., a 2 × 2 matrix of conditions). Simulations revealed distinct patterns of transactional behavior depending on the specific levels of satiation and deprivation. When deprivation levels were high and satiation levels were low, simulated transaction rates were characteristic of the high consumption rates observed with addictive commodities such as drugs. In sum, the quantitative economon model provides a framework for modeling, investigating, and predicting patterns of human transactional behavior, applicable to the trajectory of substance use disorders at an individual and group level in the context of real-world markets. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"352-362"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13002121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147473249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological and sensorimotor mechanisms linking obsessive-compulsive symptoms and cigarette smoking: A clinical laboratory study.","authors":"Melissa K Wong, Nikki S Jafarzadeh, Gregory S Chasson, Walter G Dyer, Natalia Peraza, Reid C Whaley, Marissa K Anderson, David R Strong, Mariel S Bello, Raina D Pang, Adam M Leventhal","doi":"10.1037/pha0000843","DOIUrl":"10.1037/pha0000843","url":null,"abstract":"<p><p>Obsessive-compulsive symptoms (OCS)-repeated unwanted, intrusive anxiogenic thoughts and ritualistic distress-suppressing behaviors-are comorbid with persistent cigarette smoking. This clinical laboratory experiment tested a dual-mechanism conceptualization of OCS-smoking comorbidity, which purports that people with OCS persistently smoke because they are hypersensitive to smoking's sensorimotor-ritualistic and nicotine-pharmacologic negative reinforcing properties. Cigarette-smoking adults (<i>n</i> = 129) completed a baseline session to assess clinically significant OCS (yes/no), followed by four overnight tobacco-deprived 8-hr sessions involving exposure to each of four study conditions in a within-subject 2 × 2 factorial randomized design crossing a (a) sensorimotor manipulation that modeled the tobacco self-administration ritual's effects independent of nicotine (smoking very low nicotine cigarettes [VLNC] hourly vs. no smoking) and (b) pharmacologic manipulation that modeled nicotine's effects independent of tobacco self-administration (double-blind 21 mg nicotine vs. placebo transdermal patch). Experimental session outcome measures included self-reported smoking urge (range: 0-5), nicotine withdrawal symptoms (range: 0-5), physical pain (range: 0-10), and negative affect and a behavioral task assessing motivation to reinstate usual brand cigarette smoking. Consistent with hypotheses, participants with versus without clinically significant OCS were more sensitive to the urge-suppressing effects of smoking VLNCs versus no smoking (OCS × VLNC, <i>B</i> = -.14, 95% CI [-.24, -.04]; <i>p</i> = 01) and the pain-suppressing effects of nicotine versus placebo (OCS × Nicotine, <i>B</i> = -.14, 95% CI [-.24, -.03]; <i>p</i> = 02). Counter to hypotheses, participants with clinically significant OCS experienced weaker nicotine-induced withdrawal symptom suppression (OCS × Nicotine, <i>B</i> = .16, 95% CI [.09, .24]; <i>p</i> < .001). Other OCS × VLNC or OCS × Nicotine interactions were nonsignificant. Findings from this study partially support a conceptualization that OCS-smoking comorbidity is explained by a hypersensitivity to some of smoking's nicotine-pharmacologic and sensorimotor-ritualistic negative reinforcing properties (i.e., urge and pain suppression). (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"387-396"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147473254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute effects of electronic nicotine delivery system liquid nicotine form and sweet enhancer among people who use inhaled tobacco products.","authors":"Mary A Carrico, Rabia Imran, Nicoleta Gaitan, Thokozeni Lipato, Alison Breland, Caroline O Cobb","doi":"10.1037/pha0000847","DOIUrl":"10.1037/pha0000847","url":null,"abstract":"<p><p>Research on tobacco product standards to limit the abuse liability of electronic nicotine delivery systems has primarily focused on nicotine concentration and flavor profiles. Other liquid characteristics, such as protonated nicotine ratio and sweet enhancer additives, are less understood but may serve as regulatory targets. This clinical laboratory study examined the effects of electronic nicotine delivery system protonated nicotine ratio and the presence of a sweet enhancer on nicotine delivery, use behavior, and subjective effects. Thirteen participants completed four sessions that varied by protonated ratio (0:100 vs. 40:60 freebase to protonated nicotine) and sweet enhancer content (unsweetened vs. sweetened with ethyl maltol). Each session included a 10-puff directed use period and a 30-min ad libitum use period, followed by an own brand challenge. Measures included heart rate, subjective effects, plasma nicotine concentration, and liquid consumption. Results revealed that protonated ratio significantly influenced nicotine delivery, use behavior, and subjective effects. The 0:100 conditions produced greater nicotine boost, longer puff duration, and larger puff volume compared to the 40:60 conditions. Sweet enhancer did not impact nicotine delivery but boosted flavor perception and appeal when combined with the 0:100 ratio. Unsweetened liquids were associated with greater nausea, while 40:60 conditions were perceived as harsher and more irritating. The 0:100 liquids increased concentration ratings, whereas 40:60 liquids elicited greater immediate desire to use again. These findings underscore the need for electronic nicotine delivery system product standards to consider not only nicotine concentration but also nicotine form and sweet enhancers to effectively reduce abuse liability. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"397-407"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147812845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 12-week study on the effects of betahistine (an H₃ antagonist/H₁ agonist) on cognitive functions in schizophrenia patients treated with olanzapine.","authors":"Hongyu Wang, Yongqian Wang, Weihao Huang, Wenshuang Yang, Qi Zhang, Wenxuan Zhao, Yajun Yun, Ning Fan, Jiaqi Song, Xuteng Wang, Zhiren Wang, Fude Yang","doi":"10.1037/pha0000858","DOIUrl":"10.1037/pha0000858","url":null,"abstract":"<p><p>Evidence on betahistine for cognitive impairment in schizophrenia is limited. This study evaluated its feasibility, safety, and preliminary efficacy to lay the groundwork for future randomized controlled trials. Thirty-one inpatients with schizophrenia, aged 18-60 years, undergoing treatment with olanzapine received betahistine (16 mg, three times daily) for 12 weeks. Cognitive function, clinical symptoms, and side effects were assessed at baseline and again at 12 weeks postintervention. After 12 weeks of betahistine treatment, patients with schizophrenia showed a significant increase in the total Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery score (<i>p</i> < .01). Increases were observed across multiple cognitive domains, including speed of processing, attention, working memory, verbal and visual learning, and reasoning and problem solving. Reductions in Positive and Negative Syndrome Scale scores were also observed, particularly for negative symptoms and total score (<i>p</i> < .05). Linear regression analysis revealed a significant negative correlation between age and cognitive scores (β = -0.37, <i>p</i> < .05). No adverse effects were reported. In this 12-week, single-arm study, adjunctive betahistine treatment was associated with observed improvements in cognitive performance and reductions in clinical symptom scores during the treatment period in patients with schizophrenia receiving olanzapine. Furthermore, advancing age is a key factor contributing to cognitive decline in the studied population. Betahistine was well-tolerated. This study explores betahistine as an adjunctive treatment for cognitive impairment in schizophrenia, with potential implications for improving cognitive outcomes and informing future treatment strategies. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148577639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}